

Identification of Subjects at Risk for Colorectal Carcinoma Through a Test Based on K-ras Determination in the Stool

ERICA VILLA,* AISHA DUGANI,* ANNA MARIA REBECCHI,* ANNALISA VIGNOLI,*
ANTONELLA GROTTOLA,* PAOLA BUTTAFOCO,* LORENA LOSI,[†] MARIO PERINI,* PAOLO TRANDE,*
ANNALISA MERIGHI,* RITA LEROSSE,* and FEDERICO MANENTI*

*Division of Gastroenterology, Department of Internal Medicine, and [†]Department of Pathology, University of Modena, Modena, Italy

Background & Aims: The gold standard for screening for colorectal carcinoma is colonoscopy. The aim of this study was to compare endoscopic results with those obtained using the noninvasive screening test of K-ras determination in the stool in a large population of patients undergoing colonoscopy. **Methods:** Two hundred thirty consecutive patients were studied by K-ras amplification on stool-derived DNA using polymerase chain reaction and oligomer-specific hybridization. **Results:** Wild-type K-ras was amplified in 103 of 230 patients (44.8%), the rate of amplification being directly proportional to the presence of an organic disease of the intestine characterized by hyperproliferating mucosa. In 30 of these 103 patients (29.1%), a K-ras mutation was found. Four of 5 with early colorectal carcinoma, all who had K-ras mutations in the tumor, were identified. In first-degree relatives of patients with colorectal carcinoma, all subjects either carrying adenomas >1 cm in diameter or multiple smaller adenomas were identified. In patients with inflammatory bowel disease, the test identified the only patient with neoplastic transformation. **Conclusions:** The sensitivity and specificity of K-ras determination on stool-derived DNA in patients with colorectal carcinoma, in first-degree relatives of patients with colorectal carcinoma, and in patients with inflammatory bowel disease support the opportunity of a large-scale trial to validate its use as a screening test.

Sporadic colorectal cancer (CRC) occurs in Western countries at a frequency second only to lung cancer.¹ If diagnosed at an early stage, CRC can be cured either by endoscopic excision or by surgery. The use of occult blood tests as a screening test for early identification of neoplastic lesions has shown controversial results²⁻⁸; although all trials showed an increased discovery of early colorectal cancers, only one showed a reduction in mortality.³ Therefore, there is still uncertainty about the sensitivity and specificity of this test, with some authors suggesting that a significant proportion of cancers detected may be chance discoveries.^{7,9} Colonoscopy remains the gold standard for identification of both preneoplastic and

neoplastic lesions; however, it cannot be used for mass screening because of its cost and invasiveness. Studies using colonoscopy for screening are in progress in selected populations such as patients older than 60 years of age.¹⁰

Apart from genetically determined colonic tumors, several changes in proto-oncogenes and tumor-suppressor genes have been shown in sporadic colorectal carcinogenesis¹¹ and, recently, also in colitis-associated tumors.¹² Although the model proposed for tumorigenesis suggests that it is the accumulation of multiple alterations rather than the specific order of them that is important for the development of tumor, K-ras mutations occur earlier than p53 mutations and are observed with a similar prevalence in carcinomas and in intermediate-stage adenomas.¹¹ Furthermore, most of the reported mutations cluster in a rather short fragment of DNA (i.e., the first exon of K-ras gene), making the exploration of possible mutations in genomic material derived from intestinal mucosa easier, whereas mutations of APC or p53 gene are dispersed in a rather longer fragment of DNA.¹¹

Sidransky et al.¹³ were first to report the possibility of using DNA extracted from the stool for identifying mutations of DNA derived from intestinal mucosa; they found mutations in 8 patients with colorectal tumor. We tested this method as a noninvasive screening test for colorectal tumors or colorectal adenomas in a large population of nonselected patients undergoing diagnostic colonoscopy.

Materials and Methods

Patients

Stool specimens were collected from 230 nonselected patients undergoing diagnostic colonoscopy from September 1993 to June 1994. The indications for colonoscopy were rectal bleeding in 6 patients (1 first-degree relative of a patient with

Abbreviations used in this paper: CRC, colorectal cancer; PCR, polymerase chain reaction; SDS, sodium dodecyl sulfate; SSC, standard saline citrate.

© 1996 by the American Gastroenterological Association
0016-5085/96/\$3.00

Table 1. Demographic Characteristics of Patients in the Different Categories

	CRC	History of CRC	Adenomas (including hyperplastic polyps)	History of adenomas	IBD	Lymphocytic colitis	No organic disease
No. of patients	5	31	55	67	20	6	46
Age (yr, mean $\pm$ SD)	62 $\pm$ 16	67 $\pm$ 8	59 $\pm$ 11	62 $\pm$ 10	41 $\pm$ 13	67 $\pm$ 6	50 $\pm$ 14
M/F	3/2	21/10	37/18	50/17	11/9	2/4	14/32
Personal history of tumors							
other than CRC	0/5	0/31	1/42 ^a	1/67 ^b	0/20	0/6	1/46 ^c
Family history of CRC	1/5	4/31	20/42	10/67	0/20	0/6	19/46
Family history of tumors							
other than CRC	0/5	0/31	2/42 ^{a,d}	4/67 ^{a,b,d}	0/20	0/6	2/46 ^{b,e}

^aProstate.^bLung.^cUterus.^dStomach.^ePancreas.

CRC); surveillance endoscopy after surgery for CRC in 31 patients (4 first-degree relatives of a patient with CRC); surveillance endoscopy for previously excised adenomas in 67 patients (10 first-degree relatives of patients with CRC); surveillance endoscopy for inflammatory bowel disease (IBD) follow-up in 19 patients; symptoms of irritable bowel syndrome, diarrhea, or constipation in 68 patients; and screening for family history of CRC in 39 patients.

The goal of the study was explained to the patients, and they were asked to bring a sample of stool 1 week after colonoscopy before excision of the tumor or polyp. Samples were collected and coded by personnel unaware of the results of endoscopy. Results of the molecular analysis (performed under code) and endoscopy were matched only at the end of the investigation. Stool specimens were frozen at -80°C until use.

All patients agreed to participate in the study; in a subgroup of patients with CRC, bioptic specimens were obtained for comparison with the results of the stool test. All of these patients gave written informed consent for use of the bioptic specimens not for diagnostic purposes but for use in the present study. The study was approved by the Institutional Human Research Committee of the University of Modena.

Each patient completed a questionnaire with the following information: age, sex, results of previous colonoscopies (when present), histology of adenomas (when present), previous surgery in the gastrointestinal tract for tumors, family history of intestinal tumors, and family history of tumors elsewhere than the gastrointestinal tract. These data are summarized in Table 1.

Detection of K-ras Mutations

DNA was extracted from stool specimens according to the method described by Sidransky et al.¹³ with minor modifications. Different amounts of stool specimens (100 mg, 500 mg, 1 g, and 5 g) were extracted in a pilot experiment (data not shown) to evaluate the optimal quantity of stool to use. The best results, in terms of number of positive amplifications of both K-ras and β -globin, were obtained with 100 mg.

Therefore, this amount was routinely used. Samples of stool were diluted in 300 μL lysis buffer (500 mmol/L Tris-HCl, 16 mmol/L ethylenediaminetetraacetic acid, and 10 mmol/L NaCl (pH 9.0), and particulate material was removed by centrifugation at 12,000g for 2 minutes. Proteins were digested with sodium dodecyl sulfate (SDS)–proteinase K (20 mg/mL) overnight at 37°C or for 1 hour at 65°C , extracted twice with phenol-chloroform, and ethanol precipitated. The extracted DNA (0.5–9 μg) was incubated in a total volume of 100 μL of a solution containing 10 mmol/L Tris-HCl (pH 7.2); 50 mmol/L KCl; 2 mmol/L MgCl_2 ; 500 $\mu\text{mol/L}$ each of deoxyadenosine triphosphate, deoxyguanine triphosphate, deoxycytidine triphosphate, and deoxyriboseylthymine triphosphate; 100 ng of primers located in the first *ras* exon (sense primer: 5' AGG AAT TCA TGA CTG AAT ATA AAC TTG 3'; antisense primer: 5' ATC GAA TTC CTC TAT TGT TGG ATC ATA TTC 3', giving rise to an amplified fragment of 202 base pairs), and 1 U of *Taq* DNA polymerase (Boehringer Mannheim, Milan, Italy). Forty-five cycles (30 minutes at 95°C , 3 minutes at 58°C , and 2 minutes at 70°C) were performed. Amplification products were electrophoresed through 1.8% agarose gel and ethidium bromide stained. Electrophoresed polymerase chain reaction (PCR) products were transferred to nylon membranes (Hybond N; Amersham, Milan, Italy) and prehybridized in a mixture containing 50% formamide, 5 $\times$ standard saline citrate (SSC) (0.75 mol/L NaCl and 0.075 mol/L sodium citrate), 5 $\times$ Denhardt's solution, 0.1% Ficoll (type 400; Pharmacia, Milan, Italy), 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin (fraction V; Sigma, Milan, Italy), and 50 mmol/L NaH_2PO_4 (pH 7.0) at 42°C for at least 2 hours. Hybridization was performed under stringent conditions in a mixture containing 50% formamide, 10% dextran sulfate, 5 $\times$ SSC, 1 $\times$ Denhardt's, and 20 mmol/L Na_2HPO_4 (pH 7.0) in the presence of 100 $\mu\text{g/mL}$ of denatured salmon sperm DNA at 42°C overnight. As probes, specific oligonucleotides located between the amplification primers and specific for each mutation, terminally labeled with [γ - ^{32}P] deoxyadenosine triphosphate using T4 polynucleotide kinase,

were used. Stringent washing conditions were used; after rinsing the nylon membranes in $3\times$ SSC plus 0.1% SDS at room temperature for 5 minutes, they were washed in $3\times$ SSC plus 0.1% SDS for 30 minutes at approximately 10°C below the estimated melting temperature for each probe. Autoradiography was performed for 6, 12, and 36 hours at -80°C with an intensifying screen; samples were considered positive when a clear band was present after 36 hours of exposure. No cross-hybridization was observed between the mutated probes.

As internal control for DNA origin and quality, in an initial group of 30 patients, β -globin was amplified using the following primers: sense, 5' GGT TGG CCA ATC TAC TCC AGG 3'; antisense, 5' TGG TCT CCT TAA ACC TGT CTT G 3', which give rise to an amplified fragment of 270 base pairs.

To reduce the risk of contamination and false-positive results, a number of precautions were taken as already described.¹⁴ As positive control, DNA extracted from surgical specimens of normal and neoplastic colon mucosa, known to be positive for *K-ras* mutation, were used in each run of experiment.

In 5 patients with CRC at colonoscopy, bioptic specimens of the tumor were obtained and frozen at -80°C until processed for DNA extraction. In 10 patients who had undergone surgery for CRC, tumor tissue embedded in paraffin was available for amplification; DNA was extracted as described previously¹⁴ and amplified as described in Materials and Methods.

Statistical Analysis

Data were analyzed using the χ^2 test with Yates' correction when appropriate or using two-tailed Fisher's Exact Test. A *P* value of <0.05 was considered significant.

Results

DNA obtained from 100 mg of stool ranged from 0.5 to 9 μg . Differences were present among the various groups of patients studied concerning both the purity and the total quantity recovered (Table 2).

K-ras fragments were amplified from DNA extracted from stool in 103 of 230 patients (44.7%). A *K-ras* mutation was identified in 30 of these 103 patients (29.1%); the mutation identified was Asp¹² in 21 of 30




Figure 1. (A) Ethidium bromide staining and (B) Southern blot analysis of *K-ras* fragments on DNA from the stool. DNA was amplified by PCR as described in Materials and Methods and hybridized with Asp¹²-specific probe. Lanes 1 and 2, patients with colorectal carcinoma; lane 3, patient with ulcerative colitis; lanes 4 and 5, patients with adenomas, belonging to the subgroup of CRC relatives. M, molecular weight marker; pBR 322 DNA, *Hae* III digested.

patients (70.0%; Figure 1), Val¹² in 5 (16.6%), and Asp¹³ in 4 (13.3%). Table 3 shows the percentages of amplified *K-ras* fragments and identified mutations in the patients divided according to endoscopic diagnosis.

In a subgroup of 30 patients (4 with CRC, 8 with adenomas [5 with a diameter of >1 cm, 3 with <1 cm], 4 with IBD, and 14 without endoscopic abnormalities), DNA was also amplified with β -globin primers. β -Globin was successfully amplified in all patients with CRC, in the 5 patients with adenomas >1 cm in diameter, and in the 4 patients with IBD. No amplification was obtained in patients with adenomas <1 cm in diameter, whereas a positive amplification was found in 4 of 14 patients (28.5%) without endoscopic abnormalities.

In 4 of 5 patients in whom a carcinoma (4 in T1 stage and 1 in T2 stage according to Hutter et al.¹⁵) was found, *K-ras* fragments were amplifiable; Asp¹² mutation was found in 3 of these patients, and Asp¹³ mutation was found in 1 patient.

In patients who had undergone surgery for CRC, the rate of amplification of *K-ras* fragments was significantly higher in those who had a recurrence of adenomas during follow-up than in patients without adenomas found during follow-up ($P < 0.01$) (Table 3). A higher, although not significantly different, number of *K-ras* mutations was found in patients with recurrent adenomas compared with patients without recurrences (3 of 7 vs. 3 of 24).

Among 42 subjects with adenomas at colonoscopy, *K-ras* was amplifiable in 30 (71.4%). In 19 of these patients, the polyp was single and the diameter was ≥ 1 ; in the other 11 patients, several small adenomas (4–7 mm in diameter) were present. A mutation was present in 12 patients (28.5%): 11 with adenomas ≥ 1 cm and 1 with multiple small adenomas (4–7 mm). In the 12 subjects with adenomas in whom *K-ras* fragments were not amplified, polyps were single and <8 mm in diameter.

In 67 subjects with an adenoma excised in the past,

Table 2. Characteristics of DNA Extracted From Stool

	A_{260}/A_{280}	Total amount of DNA obtained from 100 mg stool (μg)
CRC	2.0	7.3 ± 1.1
Patients undergoing surgery for CRC		
Without recurrence of polyps	1.9	3.4 ± 2.2
With recurrence of polyps	1.8	5.9 ± 2.1
Adenomas	1.9	6.4 ± 2.8
Active IBD	2.0	7.5 ± 1.6
Quiescent IBD	1.9	2.9 ± 0.8
No organic disease	1.8	1.0 ± 0.5

Table 3. Results of K-ras Amplification in All Patients Studied

	n	K-ras fragments (%)	Mutated K-ras (%)
Patients with colon cancer	5	5 (100)	4 (80.0)
Patients undergoing surgery for colon cancer	31	19 (61.2)	6 (19.3)
With adenomas during follow-up	7	7 (100) ^a	3 (42.8)
Without adenomas during follow-up	24	12 (50.0) ^a	3 (12.5)
Patients with adenomas	42	30 (71.4)	12 (28.5)
Patients with history of adenomas	67	11 (16.4)	2 (2.9)
Patients with hyperplastic polyps	13	5 (38.4)	1 (7.7)
IBD	20	13 (65.0)	3 (15.0)
Lymphocytic colitis	6	6 (100)	0
No organic diseases	46	15 (32.6)	2 (4.3)
Total	230	104 (45.2)	30 (13.0)

^a $P < 0.01$.

no adenomas were found; K-ras fragments were amplifiable in only 11 and a mutation was present in only 2 (2.9%). In 13 other patients with an adenoma excised in the past, only hyperplastic polyps were found; K-ras was amplified in 5 (38.4%), but a mutation (Asp¹³) was detected in only 1.

First-Degree Relatives of Patients With Colon Cancer

Fifty-four subjects were first-degree relatives of patients with colon cancer. The distribution of results in this subgroup of patients is shown in Table 4. The difference in the rate of amplification of K-ras fragments is particularly evident, although not significant, in patients with previous surgery for colon cancer and in patients without organic disease at colonoscopy. The difference becomes significant both in the rate of amplification of K-ras ($P < 0.05$) and in the frequency of K-ras mutations ($P < 0.01$) when the whole group of relatives of patients with colon cancer is compared with that of nonrelatives (Table 4).

In patients with adenomas, the rate of amplification

of K-ras fragments was not significantly different between the two subgroups (relatives and nonrelatives), whereas the difference in the rate of demonstration of K-ras mutations was statistically significant ($P < 0.01$) (Table 4). The diameter of the adenomas found at colonoscopy in CRC kindred was ≥ 1 cm in 12 of 20 patients; 10 of these 12 patients had K-ras mutations (83.3%). In nonrelatives, only 7 of 22 subjects had polyps > 1 cm and only 1 subject had mutations (14.0%) ($P < 0.05$, relatives vs. nonrelatives).

IBD

In patients with IBD, independently from having ulcerative colitis or Crohn's disease, there was a marked difference between patients with active and widespread disease and patients with inactive disease; K-ras fragments were amplified in a very high percentage of patients with active disease and in none with inactive disease (Table 5). Mutations were found in only 3 patients, all with pancolitis. One patient had Crohn's disease diagnosed 14 years earlier (Asp¹³). The other 2 patients (both with evidence of Asp¹² mutation) had ulcerative colitis;

Table 4. Results of K-ras Amplification in DNA From Stool From Different Categories of Patients Divided According to Presence of History of Colon Cancer in a First-Degree Relative

	CRC kindred			Nonrelatives		
	n	K-ras fragments (%)	Mutated K-ras (%)	n	K-ras fragments (%)	Mutated K-ras (%)
Patients with colon cancer	1	1 (100)	1 (100)	4	3 (75.0)	3 (75.0)
Patients undergoing surgery for colon cancer	4	4 (100)	2 (50.0)	27	15 (55.5)	4 (14.8)
Patients with adenomas	20	13 (65.0)	10 (50.0) ^a	22	17 (77.2)	2 (9.0) ^a
Patients with history of adenomas	10	2 (20.0)	1 (10.0)	57	9 (15.8)	1 (1.7)
No organic diseases	19	9 (47.3)	1 (5.2)	27	6 (22.2)	1 (3.7)
Total	54	29 (53.7) ^b	15 (27.7) ^c	137	50 (36.9) ^b	11 (8.0) ^c

^{a,c} $P < 0.01$.^b $P < 0.05$.

Table 5. Percentage of K-ras Fragments and Mutated K-ras in Patients With IBD and Lymphocytic Colitis

	n	K-ras fragments (%)	Mutated K-ras (%)
Ulcerative colitis	15		
Active disease	10	9 (90.0)	2 (20.0)
Inactive disease	5	0	0
Crohn's disease	5	4 (80.0)	1 (20.0)
Lymphocytic colitis	6	6 (100)	0

NOTE. Among the patients with ulcerative colitis, all but 1 with active disease had pancolitis.

1 patient, a 46-year-old man with ulcerative colitis diagnosed 13 years earlier, underwent colectomy for deep impairment of clinical conditions. He did not have endoscopic evidence of neoplasm, but microscopic examination of the excised colon showed three small, plaque-like carcinomas about 2 cm in diameter in the right colon. The other patient, a 55-year-old man, was diagnosed at first colonoscopy performed for rectal bleeding. Histological analysis showed polymorphs infiltrating the epithelium, mucin depletion, and a slight increase in the number of nuclei, which were also hyperchromatic. These changes were considered indefinite for dysplasia, and colectomy was delayed.

Six patients (2 men and 4 women; mean age, 67 ± 6 years) had a diagnosis of lymphocytic colitis^{16,17}; these patients had a normal endoscopic appearance apart from slight hyperemic changes. Histologically, mild inflammatory infiltrates of the surface epithelium and of the lamina propria were present. K-ras fragments were amplifiable in all of these patients, but none had evidence of K-ras mutation (Table 5).

On the whole, K-ras fragments were amplified in 54 of 56 patients (96.4%) with conditions associated with hyperproliferating mucosa and increased cellular shedding into the intestinal lumen (5 CRCs, 19 adenomas >1 cm, 11 multiple adenomas, 15 active IBD, and 6 lymphocytic colitis). Instead, this gene has been amplified in only 15 of 63 patients (23.8%) either with no organic disease (46 subjects) or with substantially benign conditions (12 small adenomas <8 mm in diameter or 5 inactive IBD). The difference is highly significant ($P < 0.0001$). K-ras mutations were also differently distributed in the two subgroups (19 of 56 vs. 2 of 62; $P < 0.001$).

Presence of K-ras Mutation in DNA From Stools and in Cancer Tissue

Colonic tissue derived from the tumoral lesion was available for investigation of K-ras mutation in all 5 patients with CRC at colonoscopy and in 10 of those

who had undergone surgery for CRC, 6 of whom had a K-ras mutation. In patients with actual CRC at colonoscopy, results of amplification on DNA from stool and from colonic tissue were the same, whereas in patients with previous surgery for CRC, PCR on DNA from stool failed to identify a K-ras mutation in 1 of 6 (16.6%) (Table 6). The only patient characterized by Asp¹³ mutation had a recurrence during the period of the study, whereas all others remained tumor-free.

Discussion

K-ras mutations have been found to occur during colorectal carcinogenesis in a stage that roughly corresponds to transition from early to intermediate adenoma; they could be involved in the conversion of small adenomas to more dysplastic ones with progression to carcinoma.^{11,18} They are mostly localized on codon 12 and, at a lesser degree, on codon 13. This clustering in a short fragment of DNA, about 150 base pairs in size, is very convenient for reliable and easy PCR amplification, even on DNA derived from stool (which could be more degraded than that derived directly from the intestinal mucosa).¹³

Table 6. Comparison Between K-ras Findings in the DNA Extracted From Stool and From Tumor Tissue of Patients With CRC and Patients With Previous Surgery for CRC

	K-ras	
	Tumor tissue	Stool
Patients with CRC		
1	Wild type	Wild type
2	Asp ¹²	Asp ¹²
3	Asp ¹²	Asp ¹²
4	Asp ¹²	Asp ¹²
5	Asp ¹³	Asp ¹³
Patients with previous surgery for CRC		
1	Wild type	Wild type
2	Wild type	Wild type
3	Wild type	Wild type
4	Wild type	Wild type
5	Asp ¹²	Asp ¹²
6	Asp ¹²	Asp ¹²
7 ^a	Asp ¹²	Asp ¹²
8 ^a	Asp ¹²	Asp ¹²
9 ^a	Asp ¹³	Asp ¹³
10	Val ¹²	Negative

NOTE. Patients with CRC were studied by PCR on DNA derived from fresh-frozen tumor tissue and patients with previous surgery for CRC by DNA extracted from paraffin-embedded tumor tissue.

^aPatients 7–9 had a recurrence of adenomas during follow-up. Patient 9 had also local tumor recurrence diagnosed 1½ years after surgery and 1 year after collection of stool for K-ras testing. No tumor tissue was available for analysis in an additional patient who had ras mutation on stool-derived DNA.

The K-*ras* amplification test on the stool proved to be very effective in the identification of subjects with early CRC carrying K-*ras* mutations. In this category of patients, the main limit of the test on stool-derived DNA is represented by the fact that only about 50% of colon cancers have K-*ras* mutations.^{19,20} However, our results show that the test can be most useful in selected populations such as in first-degree relatives of patients with colon cancer or patients with a personal history of colon cancer and recurrence of adenomas. The latter patients have an increased prevalence of *ras* mutations as shown by McLellan et al.²¹

In the group of first-degree relatives of patients with CRC, all patients but 2 with adenomas >1 cm in diameter were identified by the presence of K-*ras* mutation, a much higher percentage than that evidenced by the fecal occult blood test in a similar series of patients.^{3,7} It should be noted that the high percentage of K-*ras* mutation found in relatives is consistent with the recognized higher risk of these individuals for developing CRC.²²⁻²⁴ The high percentage of K-*ras* mutations found agrees with the figures reported in class II adenomas that have extensive high-grade dysplasia and large diameters but that have not progressed to carcinoma; these figures may range between 67% and 100%.¹⁸

The finding in patients with IBD can be related with the recent finding of an accumulation of genetic alterations similar to that occurring in sporadic colorectal carcinogenesis also in colitis-associated neoplasms.¹² Regarding K-*ras*, we have shown mutations in 50% of the cases studied; comparable percentages have been reported in other series.^{25,26} The ease of K-*ras* fragment amplification in IBD, which in turn facilitates the identification of possible mutations, strongly supports the possibility of using K-*ras* for surveillance of CRC in this subgroup of patients, considering that the fecal occult blood test in these patients is useless and that the areas that have undergone neoplastic transformation may be macroscopically unrecognizable.

The rate of amplification of K-*ras* fragments was very low in subjects with single adenomatous lesions <1 cm in diameter and in general in subjects without abnormal colonoscopic findings (such as subjects who had a small adenoma excised in the past or subjects without any organic disease). This is not surprising because only 10% of adenomas <1 cm carry K-*ras* mutations.^{22,27} Similarly, very low percentages of K-*ras* mutations have been found in patients who have undergone surgery for colon cancer without recurrent adenomas on follow-up ($P < 0.05$ vs. patients with recurrent adenomas). This finding is not a false-negative result of the test but depends on the fact that the primary tumors of these patients are character-

ized by a very low percentage of K-*ras* mutation, as already reported by Losi et al.²⁸ and Benhattar et al.²⁹ On the other hand, it is not surprising that it was possible to evidence K-*ras* mutations in the stool even after resection of the tumor; Minamoto et al.³⁰ detected *ras* mutations in the normal mucosa of about 20% of patients undergoing surgery for CRC, and Tobi et al.³¹ identified *ras* mutations in the effluent fluids of 2 of 5 patients with previous surgery for CRC. The abnormal proliferative pattern that has been found in the unaffected mucosa of these subjects, determining a higher cellular shedding into the intestinal lumen, probably favors the amplification reaction.^{32,33}

The rate of amplification of wild-type K-*ras* was very high and approached 100% in patients with IBD (both ulcerative colitis and Crohn's disease) and lymphocytic colitis. It has been shown that patients with IBD have a shortening of the turnover time and an enlargement of the proliferative compartment.^{34,35} This can result in a higher shedding of mucosal cells into the intestinal lumen with facilitated amplification of K-*ras*. The low percentage of amplification obtained in conditions usually associated with normally or nearly normal proliferating mucosa, i.e., such as in subjects without endoscopic abnormalities or subjects with history of polyps without recurrences,³⁶ may therefore be attributable to an insufficient content of intestinal cells in stool. Alternatively, it can be hypothesized that in normal subjects, DNA can undergo higher degradation by apoptosis, whereas in neoplastic cells, this mechanism is not fully operative and more DNA remains available for amplification.¹³ This second hypothesis is substantiated also by the results of β -globin amplification, which was amplified much more easily in patients with either CRC or adenomas than in normal subjects. In patients with benign or malignant adenomas, it has been repeatedly shown that epithelial cells, during progression of carcinogenic process, lose normal growth regulatory constraints and acquire an abnormal proliferative behavior with greatly increased shedding into the intestinal lumen.^{28,29} In this context, even the significantly higher percentage of amplification of K-*ras* fragments in subjects with large adenomas with high-grade dysplasia, in relatives of patients with CRC, or in patients with IBD than in subjects without any organic abnormality at the time of collection of stool may be considered important, because it is the result of an abnormally proliferating mucosa. On the other hand, an abnormal pattern of cell proliferation has been repeatedly found in each of the different categories of patients (first-degree relatives of patients with CRC and patients with IBD) in whom K-*ras* fragments have been easily amplified.³²⁻³⁸

In conclusion, the amplification of *K-ras* fragments, independently from having an associated mutation, seems to provide useful information about the status of the colon. Indeed, in the large majority of cancers, in adenomas (>1 cm), in active IBD, and in lymphocytic colitis, wild-type *K-ras* gene was amplified in almost all patients (54 of 56; 96.4%), whereas in patients with no organic disease and with small adenomas and in patients with inactive IBD, this gene was amplified in 15 of 63 subjects (23.8%). Although this gives a specificity of only 76%, the difference between the two groups is still highly significant ($P < 0.0001$). A careful follow-up of these patients is needed to try to explain the exact meaning of *K-ras* amplification in absence of demonstrable intestinal disease.

The finding of *K-ras* mutation would further reinforce the significance of amplification of *K-ras* fragments, especially in subgroups with known higher risk of colorectal carcinoma (such as first-degree relatives of patients with CRC or patients with long-standing ulcerative colitis). The possible interference of *K-ras* mutations derived from other sources (e.g., from pancreas)³⁹ should certainly be considered; in these subjects, in the presence of negative colonoscopy findings, abdominal computerized tomography would be advisable. However, the detection of *K-ras* in stool-derived DNA, as reported also by other investigators,^{31,40,41} seems sufficiently specific and sensitive to justify a large-scale trial to validate its use as a screening test.⁴²

References

- Wingo PA, Tong T, Bolden S. Cancer statistics. *CA Cancer J Clin* 1995;45:8–30.
- Winawer SJ, Andrews MNA, Flehinger B, Sherlock P, Schottenfeld D, Miller DG. Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia. *Cancer* 1980;45:2959–2964.
- Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasms: sensitivity, specificity and predictive value. Long-term follow-up in a large group practice setting. *Ann Intern Med* 1990;112:328–333.
- Thomas WM, Hardcastle JD. An update on the Nottingham trial of faecal occult blood screening for colorectal carcinoma. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. *Cancer screening*. Cambridge, England: Cambridge University, 1991:106–115.
- Kewenter J, Asztely M, Engaras B, Haglund E, Svanvik J, Ahren C. A randomised trial of fecal occult blood testing for early detection of colorectal cancer: result of screening and rescreening of 51,325 subjects. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. *Cancer screening*. Cambridge, England: Cambridge University, 1991:116–125.
- Kronborg O, Fenger C, Olsen J. Interim report on a randomised trial of screening for colorectal cancer with hemoccult-II. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. *Cancer screening*. Cambridge, England: Cambridge University, 1991:126–130.
- Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, Maillard JA, Gerstner JB, Pandya K, Ellefson RD. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and Hemoquant tests. *JAMA* 1993;269:1262–1267.
- Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. *N Engl J Med* 1993;328:1365–1371.
- Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? *JAMA* 1994;271:1011–1013.
- Ransohoff DF, Lang CA. Cost-effectiveness of one-time colonoscopy screening to reduce colorectal cancer mortality (abstr). *Gastroenterology* 1994;106:A24.
- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759–767.
- Kern SE, Redston M, Seymour AB, Caldas C, Powell SM, Kornach S, Kinzler KW. Molecular genetic profiles of colitis-associated neoplasms. *Gastroenterology* 1994;107:420–428.
- Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of *ras* oncogene mutations in the stool of patients with curable colorectal tumors. *Science* 1992;256:102–104.
- Villa E, Grottola A, Buttafoco P, Trande P, Merighi A, Fratti N, Seium Y, Cioni G, Manenti F. Evidence for HBV infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. *Dig Dis Sci* 1995;40:8–13.
- Hutter RVP, Sobin LH. A universal staging system for cancer of the colon and rectum. *Arch Pathol Lab Med* 1986;110:367–368.
- Mills LR, Schuman BM, Thompson WO. Lymphocytic colitis. A definable clinical and histological diagnosis. *Dig Dis Sci* 1993;38:1147–1151.
- Maxson CJ, Klein HD, Rubin W. Atypical forms of inflammatory bowel disease. *Med Clin North Am* 1994;78:1259–1273.
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal tumor development. *N Engl J Med* 1988;319:525–532.
- Bos JL, Fearon ER, Hamilton SR, Verlaan deVries M, Van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of *ras* gene mutations in human colorectal cancer. *Nature* 1987;327:293–297.
- Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of *K-ras* oncogenes during human colon tumorigenesis. *Nature* 1987;327:298–303.
- McLellan EA, Owen RA, Sheffield JP. High frequency of *K-ras* mutations in sporadic colorectal adenomas. *Gut* 1993;34:392–396.
- Cannon-Albright L, Skolnick MH, Bishop T, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. *N Engl J Med* 1988;319:533–537.
- Guillem JG, Forde KA, Treat MR, Neugut AI, O'Toole KM, Diamond BE. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. *Dis Colon Rectum* 1992;35:523–529.
- Neugut AI, Jacobson JS, Ahsan H, Santos J, Garbowski C, Forde KA, Treat MR, Waye J. Incidence and recurrence rate of colorectal adenomas: a prospective study. *Gastroenterology* 1995;108:402–408.
- Chen J, Compton C, Cheng E, Fromowitz F, Viola MV. *c-Ki-ras* mutations in dysplastic fields and cancers in ulcerative colitis. *Gastroenterology* 1992;102:1983–1987.
- Redstone MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE. Common occurrence of *APC* and *K-ras* gene mutations in the spectrum of colitis-associated neoplasias. *Gastroenterology* 1995;108:383–392.

27. Farr CJ, Marshall CJ, Easty DJ, Wright NA, Powell SC, Paraskeva C. A study of *ras* gene mutations in colonic adenomas from familial polyposis coli patients. *Oncogene* 1988;3:673–678.
28. Losi L, Benhattar J, Costa J. Stability of *K-ras* mutations throughout the natural history of human colorectal cancer. *Eur J Cancer* 1992;28A:1115–1120.
29. Benhattar J, Losi L, Chaubert P, Givel J-C, Costa J. Prognostic significance of *K-ras* mutations in colorectal carcinoma. *Gastroenterology* 1993;104:1044–1048.
30. Minamoto T, Yamashita N, Ochiai A, Mai M, Sugimura T, Ronai Z, Esumi H. Mutant *K-ras* in apparently normal mucosa of colorectal cancer. Its potential as a biomarker of colorectal tumorigenesis. *Cancer* 1995;75:1520–1526.
31. Tobi M, Luo F-C, Ronai Z. Detection of *K-ras* mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. *J Natl Cancer Inst* 1994;86:1007–1010.
32. Scalmati A, Roncucci L, Ghidini G, Biasco G, Ponz de Leon M. Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel. *Cancer Res* 1990;50:7937–7941.
33. Terpstra OT, Van Blankenstein M, Dees J, Eilers GAM. Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. *Gastroenterology* 1987;92:704–708.
34. Lehy T, Mignon M, Abitbol JL. Epithelial cell proliferation in the rectal stump of patients with ileorectal anastomosis for ulcerative colitis. *Gut* 1983;24:1048–1056.
35. Biasco G, Lipkin M, Minarini A, Higgins P, Miglioli M, Barbara L. Proliferative and antigenic properties of rectal cells in patients with chronic ulcerative colitis. *Cancer Res* 1984;44:5450–5454.
36. Anti M, Marra G, Armelao F, Percesepe A, Ficarelli R, Ricciuto GM, Valenti A, Rapaccini GL, De Vitis I, D'Agostino G, Brighi S, Vecchio FM. Rectal epithelial cell proliferation patterns as predictors of adenomatous colorectal polyp recurrence. *Gut* 1993;34:525–530.
37. Maskens AP, Deschner EE. Tritiated thymidine incorporation into epithelial cells of normal-appearing colorectal mucosa of cancer patients. *J Natl Cancer Inst* 1977;58:1221–1224.
38. Lipkin M. Proliferation and differentiation of normal and diseased gastrointestinal cells. In: Johnson LR, Christensen J, Jackson J, Jacobson ED, Walsh JH, eds. *Physiology of the gastrointestinal tract*. New York: Raven, 1987:255–284.
39. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of *K-ras* mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. *Cancer Res* 1994;54:3568–3573.
40. Hasegawa Y, Takeda S, Ichii S, Koizumi K, Maruyama M, Fujii A, Ohta H, Nakajima T, Okuda M, Baba S, Nakamura Y. Detection of *K-ras* mutation in DNAs isolated from feces of patients with colorectal tumors by mutant allele-specific amplification (MASA). *Oncogene* 1995;10:1441–1445.
41. Smith-Ravin J, England J, Talbot IC, Bodmer W. Detection of *c-Ki-ras* mutations in fecal samples from sporadic colorectal cancer patients. *Gut* 1995;36:81–86.
42. Sidransky D. Molecular screening—how long can we afford to wait? *J Natl Cancer Inst* 1994;84:955–956.

Received June 12, 1995. Accepted January 9, 1996.

Address requests for reprints to: Erica Villa, M.D., Division of Gastroenterology, Department of Internal Medicine, Via del Pozzo 71, 41100 Modena, Italy. e-mail: Ericavil@unimo.it. Fax: (39) 59-367627.

Supported by grant Progetti finalizzati Regione Emilia-Romagna. Dr. Dugani is a recipient of a Ph.D. fellowship of the Libyan Ministry of Education, and Drs. Buttafoco and Merighi are recipients of fellowships of the University of Modena.

The authors thank Drs. Jean Benhattar, Antonello Pietrangelo, and Maurizio Ponz de Leon for helpful discussion of the results.